57 reports

  • Immunotherapy Drugs Sales Volume
  • Chapter IV

Immunotherapy Drugs Sales Volume α-Interferon Sales Volume ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Zhejiang Beisheng Medicine Industry Hansheng Pharmaceutical Co., Ltd.

  • Chemotherapy
  • Immunotherapy
  • Pharmaceutical
  • Skin Cancer
  • Roche Group

Chapter IV KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND DEMAND Chart ##: Immunotherapy Drugs Sales Volume (million Yuan) The Immunotherapy Drugs contains two different kinds, and they are cytokines and cancer vaccines.

  • Immunotherapy
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • Roche Group
  • 8.3 IMMUNOTHERAPIES

US KEY OPINION LEADER CURRENTLY, THERE IS ONLY ONE LATE-STAGE IMMUNOTHERAPY IN THE PIPELINE THAT TARGETS MSS PATIENTS, ROCHE' S TECENTRIQ.

  • Colorectal Cancer
  • Hospital
  • Immunotherapy
  • Therapy
  • Roche Group

Topical immunotherapies are another treatment option for extensive alopecia.

  • Autoimmune Disease
  • Dermatological Condition
  • Dermatological Treatment
  • Immunotherapy
  • Roche Group
  • COTELLIC SWOT ANALYSIS, 2017
  • TECENTRIQ SWOT ANALYSIS, 2017

JOURNAL OF IMMUNOTHERAPY; ##(##): ##-##.

  • Hospital
  • Immunotherapy
  • Therapy
  • Merck & Co., Inc.
  • Roche Group

Nanda on Immunotherapy in Metastatic TNBC.

  • Breast Cancer
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Roche Group
  • a. Advent of Checkpoint Inhibitors
  • V. Advanced/Stage IV/Metastatic RCC

Combination of approved immunotherapies with new in-research immunotherapies has resulted in improved response rates for patients with RCC.

  • Cancer
  • Immunotherapy
  • Renal Cancer
  • Therapy
  • Roche Group

PLoS One; ##(##): e## Lee P, et al. (2012).

  • Immunotherapy
  • Lung Cancer
  • Targeted Therapy
  • Therapy
  • Roche Group

" When it comes to immunotherapy, I look to two distinct classes: active vaccines and passive vaccines.

  • Dementia
  • Immunotherapy
  • Eisai Co., Ltd.
  • Novartis AG
  • Roche Group
  • PLATFORMS
  • 3. INTRODUCTION

ADVAXIS IMMUNOTHERAPIES ##.

  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Ablynx NV
  • Roche Group

Morgan Table ##: Chemical Drugs vs.

  • Biotech Services
  • Immunotherapy
  • World
  • Market Size
  • Roche Group

Randomized phase II/ III trial of active immunotherapy with OPT-##/ OPT- ## in patients with metastatic breast cancer.

  • Breast Cancer
  • Cancer
  • Immunotherapy
  • Therapy
  • Roche Group

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Breast Cancer
  • Immunotherapy
  • Targeted Therapy
  • Therapy
  • Roche Group
  • 9.2 INNOVATIVE EARLY-STAGE APPROACHES

GIVEN THAT CLL CELLS HAVE ELEVATED BASELINE LEVELS OF CHECKPOINT INHIBITORY MOLECULES COMPARED TO NONCANCEROUS CELLS, SUCH AS PD-## AND ITS LIGANDS PD-L## AND PD-L## (RAMSAY ET AL., 2012), IT SEEMS LOGICAL TO EXPLORE THE EFFECTS OF IMMUNOTHERAPY VIA THE USE OF PD-##/ PD-L##

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Market Size
  • Roche Group

Ltd. and Shanghai No. ## Pharmaceutical Co.

  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Beijing Biotech Pharmaceutical Co., Ltd.
  • Roche Group

Immuno-oncology products are active immunotherapies.

  • Immunotherapy
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Roche Group

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Immunotherapy
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Roche Group

Cellular immunotherapies had two deals, while antisense RNAi oligonucleotides and antibodies had one deal each.

  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • Roche Group

Journal for ImmunoTherapy of Cancer; ##:##.

  • Immunotherapy
  • East Asia
  • Forecast
  • Market Size
  • Roche Group

One promising target for cancer treatment is the insulin-like growth factor ## receptor (IGF-##R).

  • Immunotherapy
  • China
  • Demand
  • Market Size
  • Roche Group
  • 4.4.3 SOLANEZUMAB - ELI LILLY

Immunotherapies account for only nine therapy products.

  • Clinical Trial
  • Dementia
  • Immunotherapy
  • Therapy
  • Roche Group
  • CANCER IMMUNOTHERAPIES MARKET, GLOBAL, CO-DEVELOPMENT DEALS VALUED ABOVE $100M, 2006-2016
  • CANCER IMMUNOTHERAPIES MARKET, GLOBAL, LICENSING DEALS VALUED ABOVE $500M, 2006-2016

Immunotherapy in ovarian cancer - where are we going?

  • Cancer Immunotherapy
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Roche Group

Efficacy and safety of emerging immunotherapies in psoriasis.

  • Autoimmune Disease
  • Immunology
  • Immunotherapy
  • Therapy
  • Roche Group

Journal for ImmunoTherapy of Cancer; ##(##): ##-## Kim S, et al. (2005).

  • Cancer
  • Gastric Cancer
  • Immunotherapy
  • Therapy
  • Roche Group

Low ## Low ## ## ## ## ## High ## ## ## ## High R& D High Low ## ## ## ## ## Upcoming mAbs STRATEGY STRENGTH MYLAN BUSINESS OVERVIEW Mylan was established in 1961 and is headquartered in Pennsylvania, US.

  • Breast Cancer
  • Immunotherapy
  • Therapy
  • Amgen Inc.
  • Roche Group
  • IMMUNOTHERAPEUTICS MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
  • 3.4.1 THREAT OF NEW ENTRANTS

ADDITIONALLY, THE ROLE OF IMMUNOTHERAPY AS A VIABLE OPTION FOR THE TREATMENT OF SEVERAL OTHER DISEASES WORLDWIDE IS INCREASING. ##. ##. ##. ## Mutual agreements among companies from drug ##. ##. ##. ## Increasing Importance of CART Therapies IMMUNOTHERAPY HAS EMERGED AS ONE OF THE PROMI

  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • AbbVie Inc.
  • Roche Group

From tool to therapy: a timeline of monoclonal antibody technology.

  • Immunotherapy
  • Medical Biotechnology
  • Monoclonal Antibody
  • AbbVie Inc.
  • Roche Group

For the treatment of CLL, Zydelig has been approved for use in combination with rituximab for patients who have received at least one prior therapy; or as first-line treatment in the presence of ##p deletion or TP## mutation in patients unsuitable for chemo-immunotherapy.

  • Immunotherapy
  • Lymphoma
  • Therapy
  • Gilead Sciences, Inc.
  • Roche Group

Oral anti-CD## immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-##a placebo-controlled trial.

  • Clinical Trial
  • Hepatitis
  • Immunotherapy
  • Therapy
  • Roche Group

IMMUNOTHERAPY CAN ALSO BE USED TO TARGET CSCS.

  • Cancer
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • Roche Group